Story perspectives

Pfizer Forecasts Revenue Drop Amid COVID Sales Decline

12/17/2025

Summary

Pfizer's Revenue Forecast

Pfizer Inc. projects 2026 revenue of $59.5–$62.5 billion, down from 2025's $62 billion.
The forecast reflects falling COVID-19 product sales and patent expirations that could cost $1.5 billion.
The company expects adjusted earnings per share of $2.80 to $3.00, below analyst expectations.
The company is pursuing strategic acquisitions and cost-cutting measures to stabilize its business.
CEO Albert Bourla said vaccines remain vital and declines are a temporary anomaly.

Summary

Bourla Critiques Policies

Pfizer Chief Executive Officer Albert Bourla said HHS vaccine policies affecting confidence are politically driven.
He reaffirmed Pfizer's vaccine investments despite a projected 2026 revenue decline of $59.5–$62.5 billion.
Bourla noted a 23% year-over-year drop in COVID-19 sales to about $5 billion.
He cited growth potential from acquisitions and pipeline developments despite $1.5 billion patent losses.
Bourla criticized the CDC's tarnished reputation and warned against political beliefs undermining scientific integrity.

History

Historical Context

The U.S. Vaccines for Children program, launched in 2006, dramatically improved vaccine access, resulting in a 90% decrease in vaccine-preventable diseases among children. In 2020, Pfizer partnered with BioNTech to develop a COVID-19 vaccine, achieving 95% efficacy. However, declining COVID-19 sales and patent expirations challenge Pfizer's revenue, prompting CEO Albert Bourla to address the impact of political vaccine policies on public trust.

1 of 3

Pfizer's Revenue Forecast

Pfizer Inc. projects 2026 revenue of $59.5–$62.5 billion, down from 2025's $62 billion.
The forecast reflects falling COVID-19 product sales and patent expirations that could cost $1.5 billion.
The company expects adjusted earnings per share of $2.80 to $3.00, below analyst expectations.
The company is pursuing strategic acquisitions and cost-cutting measures to stabilize its business.
CEO Albert Bourla said vaccines remain vital and declines are a temporary anomaly.

1 / 3